GlycoMimetics Inc (GLYC)

[TREND1]

***** GlycoMimetics: Undercovered With Catalysts Coming

Jun. 9, 2016 3:38 PM ET
|
2 comments
|
About: GlycoMimetics (GLYC)

William Meyers
Follow (1,085 followers)

Summary


•Lead candidate Rivipansel for VOC is in a Phase 3 trial.

•A Phase 2 trial of GMI-1271 for AML has commenced following recent positive Phase 1 results.

•A third drug IND to initiated clinical trials is expected in Q3.

•Market capitalization of $161 million looks relatively undervalued.


GlycoMimetics (NASDAQ:GLYC) is a development-stage biotechnology pharmaceuticals company generating therapy candidates with a novel platform. Its lead candidate, Rivipansel for VOC (vaso-occlusive crisis) is partnered with Pfizer for a Phase 3 trial.

GlycoMimetics stock closed at $8.03 on June 6, giving it a market capitalization of about $160 million. As a micro-cap stock it carries not only the usual risks that its clinical trials might result in failure, but also the volatility that comes from being thinly traded. I own the stock and write about it because I believe the potential upside rewards far outweigh the downside risks.

GlycoMimetics pipeline



http://seekingalpha.com/article/3981085-glycomimetics-undercovered-catalysts-coming